Cwm LLC Buys 14,139 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)

CWM LLC boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 390.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,756 shares of the biopharmaceutical company's stock after purchasing an additional 14,139 shares during the quarter. CWM LLC's holdings in PTC Therapeutics were worth $905,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PTCT. Sterling Capital Management LLC raised its stake in PTC Therapeutics by 424.4% during the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 522 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 441 shares during the period. GF Fund Management CO. LTD. bought a new stake in PTC Therapeutics in the 4th quarter valued at approximately $73,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in PTC Therapeutics in the 4th quarter valued at approximately $77,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in PTC Therapeutics in the 1st quarter valued at about $86,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Truist Financial initiated coverage on PTC Therapeutics in a research note on Tuesday, June 17th. They issued a "buy" rating and a $80.00 price target on the stock. Wells Fargo & Company raised their price target on shares of PTC Therapeutics from $68.00 to $74.00 and gave the company an "overweight" rating in a research note on Tuesday, May 27th. Robert W. Baird cut their price target on PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Citigroup upgraded shares of PTC Therapeutics from a "sell" rating to a "neutral" rating and lowered their price target for the stock from $50.00 to $40.00 in a report on Wednesday, May 7th. Finally, Royal Bank Of Canada boosted their price target on PTC Therapeutics from $57.00 to $58.00 and gave the company an "outperform" rating in a research note on Wednesday, May 7th. One analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, PTC Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $65.00.

PTC Therapeutics Stock Performance

PTCT traded down $0.97 during trading on Friday, reaching $45.35. The company's stock had a trading volume of 186,833 shares, compared to its average volume of 1,018,224. The company's fifty day moving average price is $48.89 and its 200-day moving average price is $48.51. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of 6.95 and a beta of 0.50. PTC Therapeutics, Inc. has a 52-week low of $29.01 and a 52-week high of $58.38.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, beating the consensus estimate of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $437.16 million. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The firm's revenue was down 9.6% compared to the same quarter last year. During the same period last year, the company posted ($1.20) earnings per share. Equities analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Insider Buying and Selling at PTC Therapeutics

In other news, CFO Pierre Gravier sold 2,516 shares of the company's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total value of $124,441.36. Following the transaction, the chief financial officer directly owned 71,920 shares of the company's stock, valued at approximately $3,557,163.20. This represents a 3.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Mark Elliott Boulding sold 883 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $46.02, for a total value of $40,635.66. Following the completion of the sale, the vice president directly owned 103,901 shares in the company, valued at $4,781,524.02. This trade represents a 0.84% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,328 shares of company stock valued at $254,158. 5.50% of the stock is currently owned by company insiders.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.